Robert McCarter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Robert McCarter has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Stuart Chalew
Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, USA
3 shared publications Anita Krishnan
Children's National Heart Institute, Children's National Medical Center, Washington, District of Columbia
2 shared publications- Craig Sable
Children's National Hospital
2 shared publications Alison Tompsett
Division of Cardiology, Children’s National Health System, Washington, District of Columbia, United States of America
1 shared publicationAmanda Fulgium
Division of Cardiology, Children's National Medical Center, Washington, District of Columbia
1 shared publicationAmanda L. Fulgium
Children's National Heart Institute, Children's National Medical Center, Washington, District of Columbia
1 shared publication
Latest Publications
- Open Access
- 24 June 2024
- Published by American Diabetes Association in Diabetes Care
- Vol. 47 (8) , e59-e60
Non-Hispanic Black Individuals Have Higher Glucose-Adjusted HbA1c Levels and Risk for Severe Hypoglycemia: Evidence From the Diabetes Control and Complications Trial
Robert McCarter, Stuart Chalew; Non-Hispanic Black Individuals Have Higher Glucose-Adjusted HbA1c Levels and Risk for Severe Hypoglycemia: Evidence From th Robert McCarter, Stuart Chalew; Non-Hispanic Black Individuals Have Higher Glucose-Adjusted HbA1c Levels and Risk for Severe Hypoglycemia: Evidence From th
- 24 June 2024
- Published by American Diabetes Association in Diabetes Care
- Vol. 47 (8) , e59-e60
Open AccessNon-Hispanic Black Individuals Have Higher Glucose-Adjusted HbA1c Levels and Risk for Severe Hypoglycemia: Evidence From the Diabetes Control and Complications Trial
Robert McCarter, Stuart Chalew; Non-Hispanic Black Individuals Have Higher Glucose-Adjusted HbA1c Levels and Risk for Severe Hypoglycemia: Evidence From th Robert McCarter, Stuart Chalew; Non-Hispanic Black Individuals Have Higher Glucose-Adjusted HbA1c Levels and Risk for Severe Hypoglycemia: Evidence From th
- Open Access
Firearm Deaths among Youth in the United States, 2007–2016
We sought to compare risk factors contributing to unintentional, homicide, and suicide firearm deaths in children. We conducted a retrospective review of the National Fatality Review Case Reporting System. We included all firearm deaths among children aged 0–18 years occurring from 2007 to 2016. Descriptive analyses were performed on demographic, psychosocial, and firearm characteristics and their relationship to unintentional, homicide, and suicide deaths. Regression analyses were used to compare factors contributing to unintentional vs. intentional deaths. There were 6148 firearm deaths during the study period. The mean age was 14 years (SD ± 4 years), of which 81% were male and 41% were non-Hispanic White. The most common manners of death were homicide (57%), suicide (36%), and unintentional (7%). Over one-third of firearms were stored unlocked. Homicide deaths had a higher likelihood of occurring outside of the home setting (aOR 3.2, 95% CI 2.4–4.4) compared with unintentional deaths. Suicide deaths had a higher likelihood of occurring in homes with firearms that were stored locked (aOR 4.2, 95% CI 2.1–8.9) compared with unintentional deaths. Each manner of firearm death presents a unique set of psychosocial circumstances and challenges for preventive strategies. Unsafe firearm storage practices remain a central theme in contributing to the increased risk of youth firearm deaths.
Open AccessFirearm Deaths among Youth in the United States, 2007–2016
We sought to compare risk factors contributing to unintentional, homicide, and suicide firearm deaths in children. We conducted a retrospective review of the National Fatality Review Case Reporting System. We included all firearm deaths among children aged 0–18 years occurring from 2007 to 2016. Descriptive analyses were performed on demographic, psychosocial, and firearm characteristics and their relationship to unintentional, homicide, and suicide deaths. Regression analyses were used to compare factors contributing to unintentional vs. intentional deaths. There were 6148 firearm deaths during the study period. The mean age was 14 years (SD ± 4 years), of which 81% were male and 41% were non-Hispanic White. The most common manners of death were homicide (57%), suicide (36%), and unintentional (7%). Over one-third of firearms were stored unlocked. Homicide deaths had a higher likelihood of occurring outside of the home setting (aOR 3.2, 95% CI 2.4–4.4) compared with unintentional deaths. Suicide deaths had a higher likelihood of occurring in homes with firearms that were stored locked (aOR 4.2, 95% CI 2.1–8.9) compared with unintentional deaths. Each manner of firearm death presents a unique set of psychosocial circumstances and challenges for preventive strategies. Unsafe firearm storage practices remain a central theme in contributing to the increased risk of youth firearm deaths.
- Open Access
- 24 April 2023
- Published by Wiley in Pediatric Diabetes
- Vol. 2023, 1-7
Can HbA1c Alone Be Safely Used to Guide Insulin Therapy in African Youth with Type 1 Diabetes?
Introduction. The relationship of HbA1c versus the mean blood glucose (MBG) is an important guide for diabetes management but may differ between ethnic groups. In Africa, the patient’s glucose information is limited or unavailable and the management is largely guided by HbA1c. We sought to determine if the reference data derived from the non-African populations led to an appropriate estimation of MBG from HbA1c for the East African patients. Methods. We examined the relationship of HbA1c versus MBG obtained by the continuous glucose monitoring in a group of East African youth having type 1 diabetes in Kenya and Uganda (n = 54) compared with the data obtained from A1c-derived average glucose (ADAG) and glucose management indicator (GMI) studies. A self-identified White (European heritage) population of youth (n = 89) with type 1 diabetes, 3–18 years old, living in New Orleans, LA, USA metropolitan area (NOLA), was studied using CGM as an additional reference. Results. The regression equation for the African cohort was MBG (mg/dL) = 32.0 + 16.73 × HbA1c (%), r = 0.55, . In general, the use of the non-African references considerably overestimated MBG from HbA1c for the East African population. For example, an HbA1c = 9% (74.9 mmol/mol) corresponded to an MBG = 183 mg/dL (10.1 mmol/L) in the East African group, but 212 mg/dL (11.7 mmol/L) using ADAG, 237 mg/dL (13.1 mmol/L) using GMI and 249 mg/dL (13.8 mmol/L) using NOLA reference. The reported occurrence of serious hypoglycemia among the African patients in the year prior to the study was 21%. A reference table of HbA1c versus MBG from the East African patients was generated. Conclusions. The use of non-African-derived reference data to estimate MBG from HbA1c generally led to the overestimation of MBG in the East African patients. This may put the East African and other African patients at higher risk for hypoglycemia when the management is primarily based on achieving target HbA1c in the absence of the corresponding glucose data.
- 24 April 2023
- Published by Wiley in Pediatric Diabetes
- Vol. 2023, 1-7
Open AccessCan HbA1c Alone Be Safely Used to Guide Insulin Therapy in African Youth with Type 1 Diabetes?
Introduction. The relationship of HbA1c versus the mean blood glucose (MBG) is an important guide for diabetes management but may differ between ethnic groups. In Africa, the patient’s glucose information is limited or unavailable and the management is largely guided by HbA1c. We sought to determine if the reference data derived from the non-African populations led to an appropriate estimation of MBG from HbA1c for the East African patients. Methods. We examined the relationship of HbA1c versus MBG obtained by the continuous glucose monitoring in a group of East African youth having type 1 diabetes in Kenya and Uganda (n = 54) compared with the data obtained from A1c-derived average glucose (ADAG) and glucose management indicator (GMI) studies. A self-identified White (European heritage) population of youth (n = 89) with type 1 diabetes, 3–18 years old, living in New Orleans, LA, USA metropolitan area (NOLA), was studied using CGM as an additional reference. Results. The regression equation for the African cohort was MBG (mg/dL) = 32.0 + 16.73 × HbA1c (%), r = 0.55, . In general, the use of the non-African references considerably overestimated MBG from HbA1c for the East African population. For example, an HbA1c = 9% (74.9 mmol/mol) corresponded to an MBG = 183 mg/dL (10.1 mmol/L) in the East African group, but 212 mg/dL (11.7 mmol/L) using ADAG, 237 mg/dL (13.1 mmol/L) using GMI and 249 mg/dL (13.8 mmol/L) using NOLA reference. The reported occurrence of serious hypoglycemia among the African patients in the year prior to the study was 21%. A reference table of HbA1c versus MBG from the East African patients was generated. Conclusions. The use of non-African-derived reference data to estimate MBG from HbA1c generally led to the overestimation of MBG in the East African patients. This may put the East African and other African patients at higher risk for hypoglycemia when the management is primarily based on achieving target HbA1c in the absence of the corresponding glucose data.
- 10 December 2020
- Published by Patient-Centered Outcomes Research Institute
Comparing Treatment Options for Urea Cycle Disorders
This research project is in progress. PCORI will post the research findings on this page within 90 days after the results are final. What is the research about? Urea cycle disorders are rare conditions in which the body can’t break down proteins properly. As a result, ammonia builds up in the bloodstream, which can lead to brain damage, disability, or death. Urea cycle disorders can occur in children or adults.
- 10 December 2020
- Published by Patient-Centered Outcomes Research Institute
Comparing Treatment Options for Urea Cycle Disorders
This research project is in progress. PCORI will post the research findings on this page within 90 days after the results are final. What is the research about? Urea cycle disorders are rare conditions in which the body can’t break down proteins properly. As a result, ammonia builds up in the bloodstream, which can lead to brain damage, disability, or death. Urea cycle disorders can occur in children or adults.
- 4 August 2020
- Published by Taylor & Francis in Journal of Asthma
- Vol. 58 (10) , 1384-1394
Outcomes from a pilot patient-centered hospital-to-home transition program for children hospitalized with asthma
Objective: To evaluate a multi-component hospital-to-home (H2H) transition program for children hospitalized with an asthma exacerbation. Methods: A pilot prospective randomized clinical trial of guideline-based asthma care with and without a patient-centered multi-component H2H program among children enrolled in K-8th grade on Medicaid hospitalized for an asthma exacerbation. H2H program includes 5 components: medications in-hand at discharge, school-based asthma therapy (SBAT) for controller medications, referral for home trigger assessments, communication with the primary care provider (PCP), and patient navigator support. Primary outcomes included feasibility and acceptability. Secondary outcomes included healthcare utilization, asthma morbidity, and caregiver quality of life. Results: A total of 32 children were enrolled and randomized. Feasibility outcomes in the intervention group included: medications in-hand at discharge (100%); SBAT for controller medication initiated (100%); home visit referrals made (100%) and home visits completed within 4 weeks of discharge (44%); PCP communication (100%); patient navigator communication at 3 days (81.3%) and 14 days (46.7%). Acceptability outcomes in the intervention group included: 87.5% of families continued SBAT, and 87.5% of families reported it was extremely helpful to have the home visit referral. Adjusting for baseline differences in age, asthma severity and control, there was no significant difference in healthcare utilization outcomes. Conclusion: These pilot data suggest that comprehensive care coordination initiated during the inpatient stay is feasible and acceptable. A larger trial is justified to determine if the intervention may reduce healthcare utilization for urban, minority children with asthma.
- 4 August 2020
- Published by Taylor & Francis in Journal of Asthma
- Vol. 58 (10) , 1384-1394
Outcomes from a pilot patient-centered hospital-to-home transition program for children hospitalized with asthma
Objective: To evaluate a multi-component hospital-to-home (H2H) transition program for children hospitalized with an asthma exacerbation. Methods: A pilot prospective randomized clinical trial of guideline-based asthma care with and without a patient-centered multi-component H2H program among children enrolled in K-8th grade on Medicaid hospitalized for an asthma exacerbation. H2H program includes 5 components: medications in-hand at discharge, school-based asthma therapy (SBAT) for controller medications, referral for home trigger assessments, communication with the primary care provider (PCP), and patient navigator support. Primary outcomes included feasibility and acceptability. Secondary outcomes included healthcare utilization, asthma morbidity, and caregiver quality of life. Results: A total of 32 children were enrolled and randomized. Feasibility outcomes in the intervention group included: medications in-hand at discharge (100%); SBAT for controller medication initiated (100%); home visit referrals made (100%) and home visits completed within 4 weeks of discharge (44%); PCP communication (100%); patient navigator communication at 3 days (81.3%) and 14 days (46.7%). Acceptability outcomes in the intervention group included: 87.5% of families continued SBAT, and 87.5% of families reported it was extremely helpful to have the home visit referral. Adjusting for baseline differences in age, asthma severity and control, there was no significant difference in healthcare utilization outcomes. Conclusion: These pilot data suggest that comprehensive care coordination initiated during the inpatient stay is feasible and acceptable. A larger trial is justified to determine if the intervention may reduce healthcare utilization for urban, minority children with asthma.
- Open Access
- 1 January 2020
- Published by Elsevier in SSRN Electronic Journal
Suicidality of Newer Antiseizure Medications: A Meta-Analysis
Background: Most antiseizure medications (ASMs) carry an FDA-mandated class label warning of increased suicidality risk. This is based on an FDA meta-analysis comparing suicidality between ASM and placebo (PBO)-treated subjects in PBO-controlled randomized clinical trials (RCTs) done up to 2007. New ASMs approved since then carry this warning although they were not similarly evaluated. We review all PBO-controlled phase 2 and 3 studies of 10 ASMs approved since 2008 to compare suicidality between actively vs PBO-treated patients. Methods: We reviewed primary publications and secondary safety analyses of all phase 2 and 3 RCTs in patients with treatment-resistant epilepsy for ASMs approved since 2008 for the frequency of suicidality (ideation, attempts and completed suicides).A meta-analysis compared risk for ASM vs PBO of each outcome for all drugs overall and by individual ASMs and trials. Findings: Excluding RCTs of ASMs which did not evaluate suicidality (everolimus, fenfluramine),or did not evaluate it prospectively (lacosamide, ezogabine, clobazam) we analyzed five ASMs, eslicarbazepine, perampanel, brivaracetam, cannabidiol and cenobamate. Suicidality was evaluated in 17 RCTs of these five ASMs, involving 5996 patients,4,000 actively-treated and 1996 PBO-treated. Twelve of 4000 (0.3%) ASM-treated patients had suicidal ideation, compared with 7/1996 (0.35%) of PBO-treated patients (p=0.75).Three actively treated and no PBO-treated patients attempted suicide (p=0.22).There were no completed suicides. There was no evidence of increased risk of suicidal ideation (ASM versus PBO overall RR=0.75, 95% CI 0.35,1.60) or suicide attempt (RR=0.75, 95% CI 0.30,1.87) overall or for any individual drug. Risk ratios of suicidal ideation for individual drugs vs PBO were 0.76, 0.47, 0.88 and 1.22,respectively,for eslicarbazepine, perampanel, brivaracetam and cenobamate. No suicidalities were reported with cannabidiol. Interpretation: Newer antiseizure medications do not increase suicidality in epilepsy patients. The ASM suicidality class warning is not warranted. Suicidality risk should be evaluated for each medication using validated methods in prospective studies. Labeling should be based on data from such studies and individualized for each new ASM. Funding Statement: None. Declaration of Interests: PK receives grant support from CURE/department of defense. He has received consulting or speaker fees from, or been on advisory boards of Abbot, Aquestive, Eisai, Greenwich Pharmaceuticals, Neurelis, SK Life Science, Sunovion and UCB Pharma. He is on the Medical Advisory Board of Alliance-Stratus, is on Scentific Advisory Board of OB Pharma, and is the CEO of PrevEp, LLC. Orrin Devinsky receives grant support from NINDS, NIMH, MURI, CDC and NSF. He has equity and/or compensation from the following companies: Tilray, Receptor Life Sciences, Qstate Biosciences, Tevard Biosciences, Regel Biosciences, Script Biosciences, Empatica, Engage, Papa & Barkley, Rettco, SilverSpike, and California Cannabis Enterprises (CCE). He has received consulting fees from Eisai and Zogenix. J. French receives NYU salary support from the Epilepsy Foundation and for consulting work and/or attending Scientific Advisory Boards on behalf of the Epilepsy Study Consortium for Aeonian/Aeovian, Anavex, Arvelle Therapeutics, Inc., Athenen Therapeutics/Carnot Pharma, Axovant, Biogen, BioXcel Therapeutics, Blackfynn, Cerebral Therapeutics, Cerevel, Crossject, CuroNZ, Eisai, Eliem Therapeutics, Encoded Therapeutics, Engage Therapeutics, Engrail, Epiminder, Epitel, Fortress Biotech, Greenwich Biosciences, GW Pharma, Ionis, Janssen Pharmaceutica, Knopp Biosciences, Lundbeck, Marinus, Mend NeuroscienceMerck, NeuCyte, Inc., Neurocrine, Otsuka Pharmaceutical Development, Ovid Therapeutics Inc., Passage Bio, Pfizer, Praxis, Redpin, Sage, SK Life Sciences, Sofinnova, Stoke, Sunovion, Supernus, Takeda, UCB Inc., Xenon, Xeris, Zogenix. J. French has also received research grants from Biogen, Cavion, Eisai, Engage, GW Pharma, Lundbeck, Neurelis, Ovid, Pfizer, SK Life Sciences, Sunovion, UCB, Xenon and Zogenix as well as grants from the Epilepsy Research Foundation, Epilepsy Study Consortium, and NINDS. She is on the editorial board of Lancet Neurology and Neurology Today. She is Chief Medical/Innovation Officer for the Epilepsy Foundation for which NYU receives salary support. She has received travel reimbursement related to research, advisory meetings, or presentation of results at scientific meetings from the Epilepsy Study Consortium, the Epilepsy Foundation, Arvelle Therapeutics, Inc., Biogen, Cerevel, Engage, Lundbeck, NeuCyte, Inc., Otsuka, Sage, UCB, Xenon, Zogenix. Cynthia Harden is employed by Xenon Pharmaceuticals Inc. Gregory Krauss has worked as an investigator for Cerevel Therapeutics, Eisai Labs, EpiWatch, Inc. SK Life Sciences, UCB Pharma, and as a consultant for Arvelle Therapeutics, NeuroCyte, Inc. Pled Pharma, and SK Life Science. He is a director of and owns equity in EpiWatch, Inc. Robert McCarter receives grant support from CHF/O’Malley Foundation and from NIH, and receives research support from Johns Hopkins University. Michael Sperling receives research grant and contracts from NIH, UCB Pharma, SK Life Sciences, Takeda, Neurelis, Engage Therapeutics, Medtronic, Eisai, Cavion, Cerevel, and Xenon. He has consulted for the Medtronic and the Epilepsy Study Consortium. He has received speaker fees from Eisai, Medscape, NeurologyLive, UCB Pharma, Projects in Knowledge.
- 1 January 2020
- Published by Elsevier in SSRN Electronic Journal
Open AccessSuicidality of Newer Antiseizure Medications: A Meta-Analysis
Background: Most antiseizure medications (ASMs) carry an FDA-mandated class label warning of increased suicidality risk. This is based on an FDA meta-analysis comparing suicidality between ASM and placebo (PBO)-treated subjects in PBO-controlled randomized clinical trials (RCTs) done up to 2007. New ASMs approved since then carry this warning although they were not similarly evaluated. We review all PBO-controlled phase 2 and 3 studies of 10 ASMs approved since 2008 to compare suicidality between actively vs PBO-treated patients. Methods: We reviewed primary publications and secondary safety analyses of all phase 2 and 3 RCTs in patients with treatment-resistant epilepsy for ASMs approved since 2008 for the frequency of suicidality (ideation, attempts and completed suicides).A meta-analysis compared risk for ASM vs PBO of each outcome for all drugs overall and by individual ASMs and trials. Findings: Excluding RCTs of ASMs which did not evaluate suicidality (everolimus, fenfluramine),or did not evaluate it prospectively (lacosamide, ezogabine, clobazam) we analyzed five ASMs, eslicarbazepine, perampanel, brivaracetam, cannabidiol and cenobamate. Suicidality was evaluated in 17 RCTs of these five ASMs, involving 5996 patients,4,000 actively-treated and 1996 PBO-treated. Twelve of 4000 (0.3%) ASM-treated patients had suicidal ideation, compared with 7/1996 (0.35%) of PBO-treated patients (p=0.75).Three actively treated and no PBO-treated patients attempted suicide (p=0.22).There were no completed suicides. There was no evidence of increased risk of suicidal ideation (ASM versus PBO overall RR=0.75, 95% CI 0.35,1.60) or suicide attempt (RR=0.75, 95% CI 0.30,1.87) overall or for any individual drug. Risk ratios of suicidal ideation for individual drugs vs PBO were 0.76, 0.47, 0.88 and 1.22,respectively,for eslicarbazepine, perampanel, brivaracetam and cenobamate. No suicidalities were reported with cannabidiol. Interpretation: Newer antiseizure medications do not increase suicidality in epilepsy patients. The ASM suicidality class warning is not warranted. Suicidality risk should be evaluated for each medication using validated methods in prospective studies. Labeling should be based on data from such studies and individualized for each new ASM. Funding Statement: None. Declaration of Interests: PK receives grant support from CURE/department of defense. He has received consulting or speaker fees from, or been on advisory boards of Abbot, Aquestive, Eisai, Greenwich Pharmaceuticals, Neurelis, SK Life Science, Sunovion and UCB Pharma. He is on the Medical Advisory Board of Alliance-Stratus, is on Scentific Advisory Board of OB Pharma, and is the CEO of PrevEp, LLC. Orrin Devinsky receives grant support from NINDS, NIMH, MURI, CDC and NSF. He has equity and/or compensation from the following companies: Tilray, Receptor Life Sciences, Qstate Biosciences, Tevard Biosciences, Regel Biosciences, Script Biosciences, Empatica, Engage, Papa & Barkley, Rettco, SilverSpike, and California Cannabis Enterprises (CCE). He has received consulting fees from Eisai and Zogenix. J. French receives NYU salary support from the Epilepsy Foundation and for consulting work and/or attending Scientific Advisory Boards on behalf of the Epilepsy Study Consortium for Aeonian/Aeovian, Anavex, Arvelle Therapeutics, Inc., Athenen Therapeutics/Carnot Pharma, Axovant, Biogen, BioXcel Therapeutics, Blackfynn, Cerebral Therapeutics, Cerevel, Crossject, CuroNZ, Eisai, Eliem Therapeutics, Encoded Therapeutics, Engage Therapeutics, Engrail, Epiminder, Epitel, Fortress Biotech, Greenwich Biosciences, GW Pharma, Ionis, Janssen Pharmaceutica, Knopp Biosciences, Lundbeck, Marinus, Mend NeuroscienceMerck, NeuCyte, Inc., Neurocrine, Otsuka Pharmaceutical Development, Ovid Therapeutics Inc., Passage Bio, Pfizer, Praxis, Redpin, Sage, SK Life Sciences, Sofinnova, Stoke, Sunovion, Supernus, Takeda, UCB Inc., Xenon, Xeris, Zogenix. J. French has also received research grants from Biogen, Cavion, Eisai, Engage, GW Pharma, Lundbeck, Neurelis, Ovid, Pfizer, SK Life Sciences, Sunovion, UCB, Xenon and Zogenix as well as grants from the Epilepsy Research Foundation, Epilepsy Study Consortium, and NINDS. She is on the editorial board of Lancet Neurology and Neurology Today. She is Chief Medical/Innovation Officer for the Epilepsy Foundation for which NYU receives salary support. She has received travel reimbursement related to research, advisory meetings, or presentation of results at scientific meetings from the Epilepsy Study Consortium, the Epilepsy Foundation, Arvelle Therapeutics, Inc., Biogen, Cerevel, Engage, Lundbeck, NeuCyte, Inc., Otsuka, Sage, UCB, Xenon, Zogenix. Cynthia Harden is employed by Xenon Pharmaceuticals Inc. Gregory Krauss has worked as an investigator for Cerevel Therapeutics, Eisai Labs, EpiWatch, Inc. SK Life Sciences, UCB Pharma, and as a consultant for Arvelle Therapeutics, NeuroCyte, Inc. Pled Pharma, and SK Life Science. He is a director of and owns equity in EpiWatch, Inc. Robert McCarter receives grant support from CHF/O’Malley Foundation and from NIH, and receives research support from Johns Hopkins University. Michael Sperling receives research grant and contracts from NIH, UCB Pharma, SK Life Sciences, Takeda, Neurelis, Engage Therapeutics, Medtronic, Eisai, Cavion, Cerevel, and Xenon. He has consulted for the Medtronic and the Epilepsy Study Consortium. He has received speaker fees from Eisai, Medscape, NeurologyLive, UCB Pharma, Projects in Knowledge.
- Open Access
- 24 July 2019
- Published by Elsevier in Genetics in Medicine
- Vol. 22 (1) , 219-226
Developing interactions with industry in rare diseases: lessons learned and continuing challenges
- 24 July 2019
- Published by Elsevier in Genetics in Medicine
- Vol. 22 (1) , 219-226
Open AccessDeveloping interactions with industry in rare diseases: lessons learned and continuing challenges
- Open Access
- 1 January 2018
- Published by Elsevier in SSRN Electronic Journal
Early Extra-Uterine Exposure Alters Regional Cerebellar Growth in Infants Born Preterm
Objectives: To compare third trimester global and regional cerebellar volumetric growth at two time-points between very preterm (PT) infants and healthy gestational age-matched fetuses in the PT period and at term equivalent age (TEA). Study Design: Using a prospective study design, high resolution anatomic magnetic resonance images (MRI) were acquired in PT infants (gestational age at birth<32 weeks; birthweight<1500g) and healthy full-term controls. PT infants completed two MRIs, one as soon as medically stable and the other around TEA. Controls also completed two MRIs, one in utero (i.e. fetal MRI) and a postnatal MRI shortly after birth. The injury-free cerebellum of each participant was parcellated into 5 regions: left and right hemispheres, the anterior, neo and posterior vermis. Evidence of differences in regional volumes between term and pre-term infants matched for gestational age (GA) at the time of the first MRI were assessed using multiple linear regression. Results: We studied 76 subjects: 38 PT infants were matched to 38 healthy fetuses. At MRI-1, PT infants demonstrated decreased cerebellar hemispheric volumes and increased anterior, neo- and posterior vermian regional volumes when compared to healthy fetuses. At TEA, PT infants demonstrated a persistent increase in anterior, neo- and posterior vermian regional volumes but no longer showed reductions in cerebellar hemispheric volume. Only the neo-vermis volume demonstrated a significant negative association with birthweight, male gender and supratentorial injury. Conclusions: In the absence of demonstrable cerebellar parenchymal injury evident on conventional MRI, PT birth is associated with cerebellar growth alterations that are regionally- and temporally-specific.
- 1 January 2018
- Published by Elsevier in SSRN Electronic Journal
Open AccessEarly Extra-Uterine Exposure Alters Regional Cerebellar Growth in Infants Born Preterm
Objectives: To compare third trimester global and regional cerebellar volumetric growth at two time-points between very preterm (PT) infants and healthy gestational age-matched fetuses in the PT period and at term equivalent age (TEA). Study Design: Using a prospective study design, high resolution anatomic magnetic resonance images (MRI) were acquired in PT infants (gestational age at birth<32 weeks; birthweight<1500g) and healthy full-term controls. PT infants completed two MRIs, one as soon as medically stable and the other around TEA. Controls also completed two MRIs, one in utero (i.e. fetal MRI) and a postnatal MRI shortly after birth. The injury-free cerebellum of each participant was parcellated into 5 regions: left and right hemispheres, the anterior, neo and posterior vermis. Evidence of differences in regional volumes between term and pre-term infants matched for gestational age (GA) at the time of the first MRI were assessed using multiple linear regression. Results: We studied 76 subjects: 38 PT infants were matched to 38 healthy fetuses. At MRI-1, PT infants demonstrated decreased cerebellar hemispheric volumes and increased anterior, neo- and posterior vermian regional volumes when compared to healthy fetuses. At TEA, PT infants demonstrated a persistent increase in anterior, neo- and posterior vermian regional volumes but no longer showed reductions in cerebellar hemispheric volume. Only the neo-vermis volume demonstrated a significant negative association with birthweight, male gender and supratentorial injury. Conclusions: In the absence of demonstrable cerebellar parenchymal injury evident on conventional MRI, PT birth is associated with cerebellar growth alterations that are regionally- and temporally-specific.
- 1 December 2016
- Published by Elsevier in Journal of the American Society of Echocardiography
- Vol. 29 (12) , 1197-1206
Predictive Models for Normal Fetal Cardiac Structures
- 1 December 2016
- Published by Elsevier in Journal of the American Society of Echocardiography
- Vol. 29 (12) , 1197-1206
Predictive Models for Normal Fetal Cardiac Structures